Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms)

25/11/2022
16/11/2026
EU PAS number:
EUPAS49953
Study
Finalised
Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Safety study (incl. comparative)

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medicinal product name

Study drug International non-proprietary name (INN) or common name

SPESOLIMAB

Anatomical Therapeutic Chemical (ATC) code

(L04AC22) spesolimab
spesolimab

Medical condition to be studied

Pustular psoriasis

Additional medical condition(s)

acute symptoms of generalized pustular psoriasis
Population studied

Short description of the study population

Inclusion criteria-GPP patients with acute symptoms who are administered Spesolimab I.V. Infusionin Japan
Patients who have never been treated with Spesolimab before enrolment

Age groups

  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

40
Study design details

Study design

Non-interventional cohort study

Main study objective

The primary outcome is the incidence of investigator/BI-defined drug reactions (including safety concerns: Serious infections, Serious hypersensitivity).

Setting

Sites (mainly hospitals) at which Spesolimab I.V. Infusion are available for prescription throughout entire country

Outcomes

The incidence of adverse drug reactions (ADRs)

Data analysis plan

analyses are descriptive in nature, including confidence intervals.

Summary results

In this PMS, a total of 52 patients were registered. CRFs were collected and fixed for all 52 patients. All 52 patients were included in the safety set. Of these, 51 patients were included in the effectiveness set. One patient was excluded from the effectiveness set because of “No effectiveness outcomes”.
Primary outcome
ADRs were reported in 7 of 52 patients (13.46%). ADRs were observed in 3 of 52 patients (5.77%) at <7 days and in 4 of 52 patients (7.69%) at 7 to <28 days after administration of spesolimab, whereas no ADRs were observed at ≥28 days. No ADRs were observed in the 2 patients who received the re-administration of spesolimab. No statistically significant factors associated with the occurrence of ADRs were identified in the logistic regression analysis of subgroups.